[ad#PhycoBiosciences AIM Interview]

Innovations

Sealantis’ alga-mimetic sealant in clinical study

July 22, 2013
AlgaeIndustryMagazine.com

Seal-1

Haifa, Israel-based Sealantis Ltd., a private start-up emerging from the Technion-Israel Institute of Technology, reports that eight patients have now been treated with Seal-V, its alga-mimetic vascular sealant, as part of the company’s first clinical study.

Seal-V is a protein-free sealant, designed to resolve current limitations and challenges in the control of surgical bleeding. The clinical trial, taking place in Israel, is evaluating the safety and efficacy of achieving hemostasis in large peripheral blood vessels using the Seal-V protein-free sealant.

Sealantis is a 6-year-old startup, located on the campus of one of Israel’s leading academic centers — the Technion. Sealantis was founded by Prof. Havazelet Bianco-Peled, a world-renowned expert in biomedical polymers.

Since the early 2000s, Prof. Bianco-Peled had been researching the adhesion mechanism of algae to rocks underwater. The research unveiled the chemical composition of the algae adhesive, but it was the professor’s invention of a synthetic, alga-mimetic adhesive that enabled harnessing nature’s power for practical and commercial uses.

Seal-2

In 2007, the invention was embraced by the Alfred Mann Institute at the Technion (AMIT), which is funding the company. While having potential uses in a variety of industrial applications, Sealantis chose to focus on urgent medical needs –  controlling leakage of body fluids through surgical or traumatic wounds. Such leaks can be fatal since sutures or staples are not fully leak-proof. “Sealing surgical incisions requires sticking to wet or moist surfaces, which is a challenge that most known adhesives can’t usually meet,” said Prof. Bianco-Peled.

Surgical sealants represent a market of over $1.0 billion, which grows 14% annually. “When I look at the market, it’s clear to me that there is no single winning solution,” says Dr. Zeev Gilkis, AMIT CEO and Sealantis Ltd. Chairman. “There are some good products, but each one has drawbacks or is limited to a specific application. Sealantis brings a versatile yet simple technology, addressing unmet clinical needs.”

“Seal-V is overcoming a clinical need with its unique features, which offer simultaneous sealing and hemostasis for native and synthetic vascular fields,” said Prof. Vincent Riambau, Chief of Vascular Surgery Division, Hospital Clínic, University of Barcelona, and Past President of the European Society of Vascular Surgery (ESVS), who serves on the Clinical Advisory Board of Sealantis. “It is accomplishing valuable qualities for vascular surgery, being quick, easy to use, effective and safe. It will surely be most welcome to the vascular community.”

Sealantis Ltd. is currently planning its next regulatory steps toward a PMA study and FDA approval of Seal-V and is working on strategic partnerships towards the coming market launch.”

More Like This…

HOME Algae Industry Jobs

Copyright ©2010-2013 AlgaeIndustryMagazine.com. All rights reserved. Permission granted to reprint this article in its entirety. Must include copyright statement and live hyperlinks. Contact editorial@algaeindustrymagazine.com. A.I.M. accepts unsolicited manuscripts for consideration, and takes no responsibility for the validity of claims made in submitted editorial.

From The A.I.M. Archives

— Refresh Page for More Choices
Tess Riley writes in TheGuardian.com about how spirulina may be able to combat malnutrition in developing countries. Spirulina is one of the oldest life forms on Earth, c...
Kevin Quon writes in Seeking Alpha about the financial plights and pivots of Solazyme, the algae industry’s most high profile recent IPO. In a year that started with a sh...
Green Star Products, Inc. (GSPI) has signed a contract to build a demonstration facility in Las Vegas, Nevada, to produce commercial quality algae. The Hybrid Algae Produ...
Fort Myers, FL-based Algenol has announced that the U.S. Environmental Protection Agency (EPA) has approved fuels made from Algenol’s process as an advanced biofuel, meet...
In a recent study, published in PLOS ONE Journal, the influence of light intensity on the growth and lipid productivity of Nannochloropsis salina was investigated in a fl...
Caroline Scott-Thomas reports on Food Navigator about an online algae discussion on the social media site Reddit where Mars' chief agricultural officer Howard-Yana Shapir...
Don Willmott writes in Huffington Post about Nevada-based Algae Systems, which has built a test plant on Alabama's Mobile Bay to not only turn algae into diesel fuel but ...
Hammenhög, Sweden-based agribusiness Simris Alg has announced the launch of its first consumer products. The algae farmers’ exclusive omega-3 supplements and superfoods w...
Cellana, Inc., with operations in San Diego and Kailua-Kona, Hawaii, has announced that David Anton, Ph.D., has been appointed Chief Operating Officer and elected to the ...
Sebastian Rich reports on PBS Newshour about the Central African Republic city of Bangui, which has been caught in the crossfire between warring Muslim and Christian grou...
In one of the first studies to examine the potential for using municipal wastewater as a feedstock for algae-based biofuels, Rice University scientists found they could e...
Jeff Gelski writes in foodbusinessnews.net that algae oil is now in the toolbox of alternative oils shown to replace partially hydrogenated oils (PHOs), which cause trans...
UC San Diego’s efforts to produce innovative and sustainable solutions to the world’s environmental problems have resulted in a partnership with the region’s surfing indu...
Murdoch University researchers are investigating whether the effluent from piggeries can be effectively treated with micro- and macroalgae so that species of the organism...
Using microalgae to capture CO2 is a complex process, especially in flue gas environments, reports an editorial by IEA Clean Coal Centre in worldcoal.com. There are many ...